Recent

% | $
Quotes you view appear here for quick access.

Osiris Therapeutics, Inc. Message Board

  • scistats scistats Jun 21, 2013 4:46 AM Flag

    Johnson & Johnson Simponi Crohn's -- Novartis Serelaxin Heart Failure -- Prochymal's Indications

    Is Prochymal going to hold???

    Serelaxin reduced patient deaths by 37 percent at six months after acute heart failure compared to those who received standard therapy. Novartis said late last year serelaxin was one of the most promising drugs in its pipeline, while Deutsche bank analysts said it could potentially rake in $2.5 billion in annual sales.

    Sentiment: Strong Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Good info Stats. Here's the link to study results. Always positive to extend life.
      ncbi.nlm.nih.gov/pubmed/23141816

      When Prochymal is proven to prevent Congestive Heart Failure, it will be the new paradigm. Patience is "wearing thin" waiting waiting waiting for Osir to "get off dead center" and get on with Therapeutic Prochymal partnership.

      Unless the partnership talk is a delaying tactic, the time taken is bordering on senseless. Time for OSIR to move or someone needs to lose their job.

      Sentiment: Strong Buy

 
OSIR
6.66-0.02(-0.30%)Feb 12 4:00 PMEST